David A. Siegel Passage Bio, Inc. Transaction History

Two Sigma Advisers, LP

  • $43.8 Billion
  • Q2 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$0.86 - $1.73 $774 - $1,557
-900 Reduced 0.43%
209,600 $282,000
Q4 2023

Feb 14, 2024
SELL
$0.6 - $1.01 $17,820 - $29,997
-29,700 Reduced 12.36%
210,500 $212,000
Q3 2023

Nov 14, 2023
SELL
$0.66 - $1.01 $4,950 - $7,575
-7,500 Reduced 3.03%
240,200 $158,000
Q2 2023

Aug 14, 2023
SELL
$0.82 - $1.19 $51,496 - $74,732
-62,800 Reduced 20.23%
247,700 $232,000
Q1 2023

May 15, 2023
SELL
$0.96 - $1.88 $124,416 - $243,648
-129,600 Reduced 29.45%
310,500 $298,000
Q4 2022

Feb 14, 2023
SELL
$1.06 - $1.48 $73,246 - $102,268
-69,100 Reduced 13.57%
440,100 $607,000
Q3 2022

Nov 14, 2022
SELL
$1.22 - $2.48 $87,596 - $178,064
-71,800 Reduced 12.36%
509,200 $637,000
Q2 2022

Aug 15, 2022
BUY
$1.63 - $3.46 $92,421 - $196,182
56,700 Added 10.81%
581,000 $1.37 Million
Q1 2022

May 16, 2022
BUY
$2.66 - $6.49 $248,178 - $605,517
93,300 Added 21.65%
524,300 $1.63 Million
Q4 2021

Feb 14, 2022
BUY
$6.24 - $10.2 $1.7 Million - $2.78 Million
272,500 Added 171.92%
431,000 $2.74 Million
Q3 2021

Nov 15, 2021
BUY
$9.73 - $15.52 $1.23 Million - $1.97 Million
126,800 Added 400.0%
158,500 $1.58 Million
Q2 2021

Aug 16, 2021
BUY
$12.44 - $19.45 $394,348 - $616,565
31,700 New
31,700 $420,000

Others Institutions Holding PASG

# of Institutions
46
Shares Held
32.7M
Call Options Held
8.3K
Put Options Held
400
View Full List

About Passage BIO, Inc.

PASG Quotes by TradingView
  • Ticker PASG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,463,200
  • Market Cap $37M
  • Description
  • Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...
More about PASG
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email